

Pembrolizumab KEYNOTE-158

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-158

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
 Therapeutic Indication: Patients with recurrent or metastatic cervical cancer with disease progression on or after ChT whose tumours express PD-L1 (CPS ≥ 1)
 Experimental Arm: Pembrolizumab
 Control Arm: Single arm

